Liver cancer trial aims to boost chemo effectiveness with blood pressure drug
NCT ID NCT07302919
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tests whether adding a blood pressure drug (nicardipine) to standard chemo delivered directly to the liver (TACE) can improve outcomes for people with liver cancer. About 152 adults with a single untreated tumor will be randomly assigned to receive either TACE plus nicardipine or TACE alone. The goal is to see if the combination leads to more complete tumor shrinkage and longer time without cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpitaux Universitaires de Genève
RECRUITINGGeneva, 1205, Switzerland
Contact
Contact
-
Kantonsspital St. Gallen
RECRUITINGSankt Gallen, 9007, Switzerland
Contact
Contact
-
University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.